Home Ingredients AffronEYE® (Saffron Extract for Eye Health)
Eye Health

AffronEYE® (Saffron Extract for Eye Health)

Crocus sativus
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

AffronEYE® is a standardized saffron extract for eye health developed by Pharmactive Biotech Products (Spain) — sourced from high-quality Spanish saffron and standardized to 3% crocins (the major saffron carotenoids). Distinguished by FAST absorption (maximum blood concentration in 1.5 hours, faster than lutein/zeaxanthin), water solubility, and specific evidence for early-stage age-related macular degeneration (AMD). Used for AMD, retinal flicker sensitivity, and overall macular health.

Studied Dose 20-30 mg/day saffron in clinical AMD trials; AffronEYE provides higher crocin content per gram
Active Compound Crocins (carotenoid glycosides; HPLC standardized to 3%)

Benefits

Age-Related Macular Degeneration (AMD) — Early Stage

Multiple RCTs of saffron 20-30 mg/day showed improved retinal flicker sensitivity in early-stage AMD patients. Falsini 2010 and subsequent studies established saffron-specific AMD evidence base. AffronEYE delivers standardized crocins.

Supported by Trial 1

Long-Term Open-Label AMD Extension

Recent open-label extension trial of 93 adults >50 with mild/moderate AMD showed long-term saffron treatment was safe and beneficial for ongoing AMD management. Clinical relevance for chronic AMD support.

Supported by Trial 2

Macular Pigment / Retinal Antioxidant Protection

Crocins protect photoreceptor cells from oxidative stress; cross blood-retina barrier; act as macular antioxidants protecting against blue light damage and AMD progression.

Supported by Trial 1

Fast Absorption (1.5 Hours)

Distinguishes from lutein/zeaxanthin which require longer for tissue saturation. Crocin maximum blood concentration reached in 1.5 hours after AffronEYE consumption.

Supported by Trial 1

Glaucoma Prevention (Animal Evidence)

Animal study suggests AffronEYE saffron may help prevent glaucoma onset. Early-stage evidence; clinical translation pending.

Supported by Trial 1, Trial 2

AREDS2 Adjunct / Alternative

AREDS2 supplements (lutein + zeaxanthin + zinc + antioxidant vitamins) are foundational for AMD; saffron provides complementary mechanism. AffronEYE combinable with AREDS2 protocol or used standalone.

Supported by Trial 1, Trial 2

Mechanism of action

1

Crocin Macular Antioxidant Activity

Crocins are water-soluble carotenoid glycosides — unique among carotenoids for water solubility (lutein/zeaxanthin are lipid-soluble). Cross blood-retina barrier; accumulate in retinal tissue; protect photoreceptor cells from oxidative stress.

2

Blood Flow / Microcirculation Enhancement

Crocins improve retinal microcirculation — relevant to AMD progression where retinal hypoperfusion contributes to pathology.

3

Photoreceptor Protection

Direct protection of photoreceptor cells (rods and cones) from oxidative damage and apoptosis. Mechanism for retinal flicker sensitivity improvements in AMD trials.

4

Anti-Inflammatory / Neuroprotective

Saffron compounds reduce retinal inflammation and provide neuroprotective effects relevant to AMD pathology.

5

Faster Bioavailability vs Other Carotenoids

Water solubility enables faster absorption than lipid-soluble carotenoids; rapid systemic delivery to retinal tissue.

Clinical trials

1
Saffron for AMD

Pioneering clinical trial of saffron supplementation on retinal flicker sensitivity in early AMD patients.

Early-stage AMD patients.

Significant improvement in retinal flicker sensitivity vs placebo. Established saffron's specific eye health applications. Foundation for AffronEYE positioning.

2
Saffron AMD Long-Term Extension Study

Open-label extension trial of saffron in 93 adults >50 with mild/moderate AMD for long-term safety and efficacy.

93 adults >50 with mild/moderate AMD.

Long-term saffron treatment safe and beneficial for ongoing AMD management. Established chronic-use evidence.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress (rare).
Allergic reactions to Asteraceae family rare.
Mood effects (saffron is also antidepressant — modest).
Theoretical bleeding at high doses.

Important Drug interactions

Antidepressants — saffron has serotonergic activity; theoretical additive effects.
Anticoagulants — modest antiplatelet effects.
Pregnancy — saffron generally cautioned in pregnancy at supplemental doses (uterotonic at very high doses); avoid supplementation.
Lactation — limited data; avoid supplementation.
Antihypertensives — modest BP effects.

Featured in these supplement guides

Eye Health→

More Eye Health Ingredients

Eye Health
FloraGLO® Lutein (Kemin)
FloraGLO® Lutein (Kemin Industries) is the most clinically studied lutein extract — derive…
Eye Health
OPTISHARP™ Natural Zeaxanthin (Kemin/DSM)
OPTISHARP™ Natural is natural zeaxanthin sourced from marigold flowers — co-marketed by Ke…
Eye Health
ZeaONE® (Natural Zeaxanthin from Marigold)
ZeaONE® is the source OF natural zeaxanthin from marigold flowers manufactured by Kemin In…
Eye Health
Lutemax® 2020 (Lutein + Both Zeaxanthins — OmniActive)
Lutemax® 2020 is OmniActive's patented macular carotenoid ingredient extracted from marigo…

Explore Other Ingredients

Antioxidant
Setria® Glutathione
Setria® is Kyowa Hakko's patented reduced L-glutathione (GSH) produced via fermentation —…
Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…
Cognitive
Rhodiola Rosea
Rhodiola rosea is an adaptogenic herb traditionally used in cold northern regions to comba…

Related articles from our blog

📝 Article
Saffron for Mood: What the Research Shows on Depression and Anxiety
Saffron is best known as the world's most expensive spice, the crimson threads that color and perfume a paella or a Pers…

Frequently asked questions about AffronEYE® (Saffron Extract for Eye Health)

What is AffronEYE?

AffronEYE® is a standardized saffron extract for eye health developed by Pharmactive Biotech Products (Spain) — sourced from high-quality Spanish saffron and standardized to 3% crocins (the major saffron carotenoids). Distinguished by FAST absorption (maximum blood concentration in 1.

What is AffronEYE used for?

AffronEYE is researched primarily for Eye Health. Multiple RCTs of saffron 20-30 mg/day showed improved retinal flicker sensitivity in early-stage AMD patients. Falsini 2010 and subsequent studies established saffron-specific AMD evidence base. AffronEYE delivers standardized crocins.

What is the recommended dosage of AffronEYE?

The clinically studied dose is 20-30 mg/day saffron in clinical AMD trials; AffronEYE provides higher crocin content per gram Always follow the product label and check with a healthcare provider for personal advice.

Is AffronEYE safe, and does it have side effects?

For most healthy adults, AffronEYE is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Mild GI distress (rare). It may also interact with some medications. AffronEYE is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does AffronEYE interact with any medications?

Possible interactions include: Antidepressants — saffron has serotonergic activity; theoretical additive effects. Anticoagulants — modest antiplatelet effects. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for AffronEYE?

NutraSmarts rates the evidence for AffronEYE as Strong (4 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Broadhead GK, Grigg JR, McCluskey P, Hong T, Schlub TE, Chang AA. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Graefes Arch Clin Exp Ophthalmol. 2019;257(1):31-40. doi: 10.1007/s00417-018-4163-x.PubMedUsed to support: Largest saffron-AMD RCT (n=100, double-blind placebo-controlled crossover); 20 mg/day saffron modestly improved best-corrected visual acuity and microperimetry in mild/moderate AMD, including patients already on AREDS supplements, supporting the eye-health claim though effect sizes were small.
  2. Lashay A, Sadough G, Ashrafi E, Lashay M, Movassat M, Akhondzadeh S. Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial. Med Hypothesis Discov Innov Ophthalmol. 2016;5(1):32-38..PubMedUsed to support: Small RCT (n=60, dry and wet AMD) where 30 mg/day saffron produced a statistically significant improvement in ERG amplitude at 3 months versus placebo, backing the retinal-function claim; benefits partly attenuated by 6 months and the journal is low-impact.
  3. Marangoni D, Falsini B, Piccardi M, Ambrosio L, Minnella AM, Savastano MC, et al. Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report. J Transl Med. 2013;11:228. doi: 10.1186/1479-5876-11-228.PubMedUsed to support: Open-label study (n=33) showing 20 mg/day saffron significantly improved focal-ERG macular flicker sensitivity in early AMD irrespective of CFH/ARMS2 risk genotype, supporting the retinal-function claim; preliminary, small, and not placebo-controlled.
  4. Piccardi M, Marangoni D, Minnella AM, Savastano MC, Valentini P, Ambrosio L, et al. A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function. Evid Based Complement Alternat Med. 2012;2012:429124. doi: 10.1155/2012/429124.PubMedUsed to support: Longitudinal study (n=29) reporting 20 mg/day saffron sustained focal-ERG improvements in central retinal function over ~14 months in early AMD, backing the durable retinal-benefit claim; small open-label sample with no concurrent placebo arm.